摘要Phage display technology allows for rapid selection of antibodies from the large repertoire of human antibody fragments displayed on phages.However,antibody fragments should be converted to IgG for biological characterizations and affinity of antibodies obtained from phage display library is frequently not sufficient for efficient use in clinical settings.Here,we describe a new approach that combines phage and mammalian cell display,enabling simultaneous affinity screening of full-length IgG antibodies.Using this strategy,we successfully obtained a novel germline-like anti-TIM-3 monoclonal antibody named m101,which was revealed to be a potent anti-TIM-3 therapeutic monoclonal antibody via in vitro and in vivo experiments,indicating its effectiveness and power.Thus,this platform can help develop new monoclonal antibody therapeutics with high affinity and low immunogenicity.